Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$20.45M
38.85K shares · 0.0% of portfolio
Idexx Laboratories Inc
Idexx Laboratories Inc (IDXX) is listed on NASDAQ and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Westbrook, United States and has 11,000 employees. The company is worth $44.65B and trades at 39.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $4.3B in fiscal 2025, up 10.4% from the year before. Net income was $1.06B. The share price is 26.4% below its 52-week high of $769.98. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Baillie Gifford (Baillie Gifford & Co), at $186.25M. In that quarter, 5 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -7.8% over 5Y.
today you would have $841.20▼ -15.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $676.53 | $413.44 | $555.05 | $407.96 | $658.46 | $499.87 | $261.13 | $186.02 | $156.38 | $117.27 | $72.92 | $74.14 | $53.19 | $46.40 | $38.48 | $34.61 | $26.73 | $18.04 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 14.3% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 42.5 across this company’s own years on record.
Cash flow growing 14.3% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| WATWaters Corp | $455.59 | 115.9x | 2.9x | 0.00% | 1.92% | $44.73B |
| HLNHaleon plc | $10.37 | 21.2x | 2.1x | 1.93% | 10.09% | $45.6B |
| IQVIqvia Holdings Inc | $278.32 | 34.4x | 7.4x | 0.00% | 22.82% | $45.81B |
| ONCBeOne Medicines Ltd. | $382.27 |
| P/E | 42.5x | 51.7x | 38.7x | 55.2x | 50.8x | 76.6x | 74.5x | 53.4x | 43.7x | 53.2x | 48.1x | 35.6x | 41.4x | 30.6x | 29.3x | 27.7x | 29.2x | 26.6x | 19.3x |
| P/S | 6.4x | 12.5x | 8.6x | 12.6x | 10.0x | 17.3x | 15.8x | 9.3x | 7.2x | 6.9x | 5.8x | 4.1x | 4.7x | 4.0x | 3.9x | 3.5x | 3.6x | 3.1x | 2.2x |
| P/B | 26.1x | 33.6x | 21.1x | 31.1x | 55.6x | 80.4x | 67.6x | 125.6x | — | — | — | — | 59.5x | 10.6x | 8.0x | 7.9x | 6.9x | 6.3x | 5.1x |
| EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 | $2.05 | $1.79 | $1.74 | $1.59 | $1.39 | $1.19 | $1.01 | $0.94 |
| Profit margin | 13.71% | 24.62% | 22.78% | 23.08% | 20.17% | 23.17% | 21.49% | 17.77% | 17.04% | 13.36% | 12.51% | 11.99% | 12.24% | 13.64% | 13.78% | 13.28% | 12.80% | 11.85% | 11.34% |
| ROE | 56.29% | 65.99% | 55.65% | 56.92% | 111.56% | 107.95% | 92.04% | 241.01% | — | — | — | — | 154.79% | 36.24% | 28.02% | 29.98% | 24.60% | 23.75% | 26.51% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-41.3% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 69.1x |
| 8.4x |
| 0.00% |
| 14.66% |
| $43.49B |
| TEVATEVA Pharmaceutical Industries Ltd | $40.21 | 67.0x | 6.0x | 0.00% | 9.69% | $46.9B |
| MDLNMedline Inc. | $34.88 | 87.2x | 2.6x | 0.00% | 4.93% | $46.93B |
